RetinAI
Edit

RetinAI

http://retinai.com/
Last activity: 16.10.2024
Active
Categories: Artificial IntelligenceCareDataHealthTechManagementMedTechPlatformResearchSoftwareTime
RetinAI builds software to collect, organise & analyse health data from the eyes, empowering healthcare professionals, pharmaceutical companies & patients with unique data analysis supported by AI. We bring AI to the retina specialist and healthcare professional for retinal diseases like A
Mentions
44
Location: Switzerland, Bern
Total raised: $8.5M

Investors 5

Funding Rounds 2

DateSeriesAmountInvestors
02.05.2024Series A$6.18M-
11.06.2019-$2.32M-

Mentions in press and media 44

DateTitleDescription
16.10.2024Ikerian Holds Series B Funding First Close of USD 8M(left) Carlos Ciller, PhD, CEO, co-founder and Chairman Ikerian AG and RetinAI US Inc.; (center) Stefanos Apostolopoulos, PhD, CTO and co-founder Ikerian AG and RetinAI US Inc.; (right) Sandro De Zanet, PhD, Chief Scientific Officer and co-...
03.07.2024Ikerian secures EU MDR Certificate for multiple assets Ikerian AG, the parent company of RetinAI U.S. Inc, develops software solutions for the ophthalmology and optometry market to collect, organize and analyse health data from the eyes. Its solutions, RetinAI Discovery®, a transformative heal...
02.05.2024Ikerian AG Closes Series A Extension FinancingIkerian AG, the parent company of RetinAI U.S. Inc., has successfully closed its Series A Extension financing, bringing in a total of USD 6.18M (CHF 5.65M) from new and existing investors. The lead investor for this final close was the Corp...
02.05.2024Ikerian secures USD 6.18 million Series A extension Financing to advance AI-driven healthcare solutionsIkerian secures USD 6.18 million Series A extension Financing to advance AI-driven healthcare solutions 02.05.2024 09:05, Rita Longobardi linkedIn facebook twitter instagram youtube --> Ikerian, the parent company of retinal disease anal...
02.05.2024Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension FinancingRetinAI Medical AG rebranded as Ikerian AG “Ikerian”, to spearhead development beyond ophthalmology, with wholly-owned subsidiary RetinAI U.S. Inc. “RetinAI” focused on the ophthalmology and optometry market. Ikerian’s Series A Extension fi...
02.05.2024Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing-
02.05.2024Ikerian raises USD 6.18M in Series A Extension Financing round The final close was led by a strategic investor: the Corporate Venture Capital arm of Topcon Healthcare, Inc. The first close in 2023 added Zürcher Kantonalbank (ZKB) as a new investor alongside existing Seed and Series A venture firms, th...
21.02.2024RetinAI Discovery Platform and AI tools Launched to Improve Decision Workflows, Referrals and Patient ManagementIkerian AG and RetinAI Inc. US, a leader in developing software solutions for image processing and artificial intelligence (AI) in Ophthalmology, has launched RetinAI Discovery for Clinics, with two product versions to address the needs of ...
13.11.2023RetinAI’s Discovery platform deployed in two landmark initiatives
27.07.2023Swiss startups conquer new markets with global partners
Show more

Reviews 0

Sign up to leave a review

Sign up Log In